Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Gut. 2015 Mar 16;65(6):925–934. doi: 10.1136/gutjnl-2014-308416

Figure 1. DARPP-32 proteins up-regulate ANGPT2 expression in gastric cancer cells without activating NF-κB signal pathway.

Figure 1

A–B) The qRT-PCR and Western blot analysis of ANGPT2 mRNA (left panels) and protein (right panels) levels in AGS cells transiently overexpressing DARPP-32 (DP32), DARPP-32T34A mutant (DP32T34A), or t-DARPP (TDP). Error bars indicate standard deviation (SD), * P<0.05, ** P<0.01 compared with control (One way ANOVA). C) Western blot analysis of ANGPT2, DARPP-32, and t-DARPP in AGS/Tet-on cells stably expressing empty vector (Ctrl), DARPP-32 (DP32), and t-DARPP (TDP). D–E) The qRT-PCR and Western blot analysis of ANGPT2 expression in AGS cells transiently overexpressing DARPP-32, t-DARPP, or control with or without TNF-α treatment; * P<0.05, ** P<0.01, *** P<0.001 compared with control (One way ANOVA). F) Western blot analysis showing phospho-P65 (S536) (P-P65), P65, DARPP-32, and t-DARPP in AGS cells transiently overexpressing DARPP-32, t-DARPP, or control with or without TNF-α treatment. G) NF-κB luciferase reporter analysis in AGS cell stably expressing pGL4.32 [luc2P/NF-κB-RE/Hygro] and transiently overexpressing DARPP-32, t-DARPP, or control treated with or without TNF-α; NS, not significant.